Company: Mitochon Pharmaceuticals
Job title: Founder & Chief Scientific Officer
John G. Geisler, Ph.D., Founder & Chief Scientific Officer, Mitochon Pharmaceuticals, Inc. – Expertise in drug discovery in metabolic disease (Pfizer, Ionis, JnJ) with a primary role bringing forward the inception of new ideas. By striving to working at the root of problems and years of attempting to partition lipids to restore insulin sensitivity, Dr. Geisler has built an expertise in mitochondrial energy expenditure. From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders, neurodegenerative diseases, and trauma. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), and a dual fellowship at Pfizer & Yale University, focused on the physiology of Type-2 diabetes and whole-body flux. Mitochon Pharmaceuticals was launched Nov 2014 along with co-founder, Robert Alonso and currently in Phase I to test the safety and tolerability of MP-101 (2, 4 dinitrophenol) in NHV. With successful completion, Mitochon is planning for a series of Phase IIa biomarker studies to test the merits of MP-101 to lower damage caused by mitochondria dysfunction and increase biogenesis/neurotrophins for repair in ALS, Huntington’s and Alzheimer’s Disease participants.
Meaningful Pleiotropic Pharmacology for Truly Insidious Pleiotropic Diseases 10:00 am
• Examine how MP101 & MP201 lowers mitochondrial calcium overload, mTOR and ROSs that drive apoptosis • Observe how MP101 & MP201 increase cognitive factors: cAMP, CREB and BDNF that pushes repair • Analyze how MP101 & MP201 wake up compensatory mechanisms prosurvival as an oral once-per-day brain penetrating small moleculeRead more
day: Day Two